Cetuximab in squamous cell head and neck carcinomas

Annals of Oncology

Volumn 18, Issue SUPPL. 6, 2007, Pages

  Gebbia, Vittorio ^a,b   Giuliani, F ^c   Valori, V M ^d   Agueli, R ^a   Colucci, G ^c   Maiello, E ^d  

^a LA MADDALENA CANCER CENTER   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Cetuximab; Chemotherapy; EGFR; Head and neck cancer; Patient outcome; Toxicity

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; FLUOROURACIL; PACLITAXEL; PLACEBO; PLATINUM; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; RADIOSENSITIZING AGENT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BACTEREMIA; CANCER CONTROL; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FOLLICULITIS; HEAD AND NECK CARCINOMA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LEUKOPENIA; LIVER TOXICITY; LOADING DRUG DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; RADIOSENSITIZATION; RECURRENT CANCER; SIGNAL TRANSDUCTION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; ANIMAL; HEAD AND NECK TUMOR; METASTASIS; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; TUMOR RECURRENCE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; RADIATION-SENSITIZING AGENTS;

EID: 35748985892     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm215     Document Type: Conference Paper

References (23)

1. Ang KK, Berkey BA, Tu X et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350-7356.
2. Chung CH, Ely K, McGavran L et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24(25): 4170-4176.
3. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935-1940.
4. Milas L, Mason K, Hunter N et al. In vivo enhancement of tumor radio-response by C225 anti-epidermal growth factor receptor antibody. Clin Cancer Res 2000; 6: 701-708.
5. Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001; 49: 427-433.
6. Harari PM, Huang SM. Combining EGFR inhibitors with radiation or chemotherapy: Will preclinical studies predict clinical results? Int J Radiat Oncol Biol Phys 2004; 58: 976-983.
7. Harari PM, Huang SM. Combining EGFR inhibitors with radiation or chemotherapy: Will preclinical studies predict clinical results? Int J Radiat Oncol Biol Phys 2004; 58: 976-983.
8. Robert F, Ezekiel MP, Spencer SA et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19(13): 3234-3243.
9. Bourhis J. New approaches to enhance chemotherapy in SCCHN. Ann Oncol 2005; 16 (Suppl 6): Vi20-vi24.
10. Gebbia V, Mantovani G, Farris A et al. Vinorelbine, cisplatin, and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck: Results of a phase II multicenter study. Cancer 1997; 79(7): 1394-1400.
11. Harari PM. Promising new advances in head and neck radiotherapy. Ann Oncol 2005; 16 (Suppl 6): Vi13-vi19.
12. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New Engl J Med 2006; 354: 567-578.
13. Pfister DG, Su YB, Kraus DH et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006; 24(7): 1072-1078.
14. Kies MS, Garden AS, Holsinger C et al. Induction chemotherapy (CT) with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck (HN). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006; 24 (Suppl 18): 5520.
15. Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004; 22: 1743-1752.
16. Gebbia V, Mantovani G, Cognetti F et al. Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: A multicenter phase II trial. Ann Oncol 1995; 6(10): 987-991.
17. Bourhis J. New approaches to enhance chemotherapy in SCCHN. Ann Oncol 2005; 16 (Suppl 6): Vi20-vi24.
18. Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18: 904-914.
19. Trigo J, Hitt R, Koralewski P et al. Cetuximab monotherapy is active in patients (pts) with platinum-retractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. ASCO Annual Meeting Proceedings. J Clin Oncol 2004; 22 (Suppl 14): (Abstr 5502).
20. Baselga J, Trigo JM, Bourhis J et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antbody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5568-5577.
21. Herbst RS, Arquette M, Shin DM et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23(24): 5578-5587.
22. Burtness B, Goldwasser MA, Flood W et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23(34): 8646-8654.
23. Cohen EW. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2659-2665.